PR Newswire Clinical TrialsOriginal article
ERA-Kongress: Die FLOW-Studie zeigt, dass Semaglutid die Lebensqualität bei Diabetes und Nierenerkrankungen verbessert
Data ReadoutpositiveSemaglutidPositive
AI Analysis
Summary
The FLOW study presented at the 63rd ERA Congress demonstrates that once-weekly semaglutid improves health-related quality of life in adults with Type 2 Diabetes and chronic kidney disease. This positive data readout supports the clinical benefits of semaglutid in this patient population.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
FLOW study demonstrates semaglutid improves health-related quality of life in adults with Type 2 Diabetes and kidney disease
Importance:7/10
Sentiment:
0.75
FLOW-StudySemaglutidType 2 DiabetesChronic Kidney DiseaseQuality of LifeERA CongressClinical Data
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on June 3, 2026 10:01 PM